VanderWeideLAFosterCJMacLarenR. Evaluation of early dexmedetomidine addition to the standard of care for severe alcohol withdrawal in the ICU: a retrospective controller cohort study. J Intensive Care Med. 2016;31(3):198–204.
2.
MuellerSWPreslaskiCRKiserTH. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med. 2014;42(5):1131–1139.
3.
CrispoALDaleyMJPepinJLHarfordPHBrownCV. Comparison of clinical outcomes in nonintubated patients with severe alcohol withdrawal syndrome treated with continuous-infusion sedatives: dexmedetomidine versus benzodiazepines. Pharmacotherapy. 2014;34(9):910–917.
4.
LudtkeKAStanleyKSYountNLGerkinRD. Retrospective review of critically ill patients experiencing alcohol withdrawal: dexmedetomidine versus propofol and/or lorazepam continuous infusions. Hosp Pharm. 2015;50(3):208–213.
5.
LizotteRJKappesJABartelBJHayesKMLesselyoungVL. Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal. Clin Pharmacol. 2014;6:171–177.
6.
DouglasI. Dexmedetomidine (Precedex®) for severe alcohol withdrawal syndrome (AWS) and alcohol withdrawal delirium (AWD). Clinicaltrials.gov. Web site. https://clinicaltrials.gov/ct2/show/record/NCT01362205. Published May 24, 2010. Updated February 6, 2016. Accessed March 10, 2016.
